Nektar Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $24,124 | $23,489 | $21,639 | $23,885 |
Gross Profit | 19,689 | 13,749 | 13,105 | 16,602 |
EBITDA | -34,345 | -44,450 | -29,699 | -33,589 |
EBIT | -35,338 | -45,909 | -31,306 | -35,241 |
Net Income | -37,057 | -52,363 | -36,802 | -42,079 |
Net Change In Cash | 24,124 | 23,489 | 21,639 | 23,885 |
Free Cash Flow | -44,598 | -37,888 | -48,045 | -47,284 |
Cash | 30,109 | 13,920 | 34,744 | 20,161 |
Basic Shares | 209,249 | 208,828 | 194,746 | 191,040 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $90,122 | $92,055 | $101,907 | $152,915 |
Gross Profit | 53,478 | 70,420 | 77,010 | 133,438 |
EBITDA | -243,107 | -323,872 | -462,967 | -394,329 |
EBIT | -250,922 | -336,072 | -475,967 | -406,829 |
Net Income | -276,056 | -368,198 | -523,837 | -444,440 |
Net Change In Cash | 90,122 | 92,055 | 101,907 | 152,915 |
Cost of Revenue | -173,645 | 102,572 | ||
Free Cash Flow | -193,471 | -309,683 | -427,649 | -320,545 |
Cash | 35,277 | 88,227 | 25,218 | 198,955 |
Basic Shares | 190,001 | 187,138 | 183,298 | 178,581 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.18 |
2024-06-30 | -$0.25 |
2024-03-31 | -$0.19 |
2023-12-31 | -$0.22 |
